Clinical Trial Update: Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing early rising PSA endocrine treatment versus chemo-endocrine therapy (SPCG14) for prostatic neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Göteborg University | Conditions: Prostatic Neoplasms | Phase 3 | Status: UNKNOWN